N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
1. A method for preventing and/or treating hot flashes in a patient, comprising administering to a patient in need thereof for at least four weeks a pharmaceutically effective amount of a compound selected from the group consisting of:
wherein the frequency of hot flashes in the patient after at least four weeks of treatment is reduced compared to the frequency of hot flashes in the patient before at least four weeks of treatment.
2. The method according to claim 1 , wherein the hot flashes are related to a condition selected from the group consisting of a perimenopausal condition, a menopausal condition, and a postmenopausal condition, or a combination thereof.
3. The method according to claim 1 , wherein the hot flashes are a consequence of hormone therapy which intentionally lowers the level of sex hormones.
4. The method according to claim 3 , wherein the hot flashes are selected from the group consisting of therapy-induced hot flashes in breast cancer, therapy-induced hot flashes in uterine cancer, and therapy-induced hot flashes in prostate cancer.
5. The method according to claim 1 , wherein the compound is selected from the group consisting of:
6. The method according to claim 1 , wherein the compound is:
7. A method for preventing and/or treating hot flashes in a patient, comprising administering to a patient in need thereof for at least four weeks a pharmaceutically effective amount of a compound selected from the group consisting of:
wherein the severity of hot flashes in the patient after at least four weeks of treatment is reduced compared to the severity of hot flashes in the patient before at least four weeks of treatment.
8. The method according to claim 7 , wherein the hot flashes are related to a condition selected from the group consisting of a perimenopausal condition, a menopausal condition, and a postmenopausal condition, or a combination thereof.
9. The method according to claim 7 , wherein the hot flashes are a consequence of hormone therapy which intentionally lowers the level of sex hormones.
10. The method according to claim 9 , wherein the hot flashes are selected from the group consisting of therapy-induced hot flashes in breast cancer, therapy-induced hot flashes in uterine cancer, and therapy-induced hot flashes in prostate cancer.
11. The method according to claim 7 , wherein the compound is selected from the group consisting of:
12. The method according to claim 7 , wherein the compound is: